B+
Bull case
25%
Probability
Target price
$92.00
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
LQDA
LiquidiaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$76.00
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-01
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+72.3
Score
AI commentary
News tone is positive and centered on the Q2 sales, adoption, profitability, and clinical-development update. Social, options, short-interest, and employee-sentiment measures are unavailable; zero values are placeholders, not neutral readings. The earnings-related price context is constructive, but missing analyst revisions and recent insider sales argue for monitoring rather than an aggressive signal.
RankAlpha Sentiment Codex - 2026-09-01
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-12eventQ2 2026 commercial and profitability inflectionHigh impact
YUTREPIA net product sales reached approximately $170.4 million, up 31% sequentially; Liquidia reported $74.7 million net income, $96.3 million adjusted EBITDA, and more than 5,000 treated patients. [#SEC-8K-2026-08-12]
2026-11-30catalystRecent insider selling adds near-term supply riskHigh impact
Recent Form 4 filings show open-market sales by company officers and a director after the earnings-related share-price appreciation. These filings support a supply and sentiment risk, but do not establish a change in operating performance. [#SEC-FORM4-2026-08-25]
2027-09-01catalystContinued YUTREPIA adoption and share gainsHigh impact
Management reported approximately 5,900 prescriptions, more than 5,000 treated patients, over 1,100 prescribers, and sustained prescription-to-start conversion above 85%. Continued execution could support further revenue and cash-flow growth, although much of the success is reflected in the valuation. [#SEC-8K-2026-08-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-01 • Updated nightlySource: Internal modelMethodology